DarioHealth Corp. (NASDAQ:DRIO) Short Interest Down 24.6% in February

DarioHealth Corp. (NASDAQ:DRIO) saw a significant decline in short interest in February. As of February 27th, there was short interest totaling 50,473 shares, a decline of 24.6% from the February 12th total of 66,964 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 8,089 shares, the days-to-cover ratio is currently 6.2 days. Based on an average daily volume of 8,089 shares, the days-to-cover ratio is currently 6.2 days. Currently, 0.8% of the shares of the stock are sold short.

DarioHealth Price Performance

Shares of NASDAQ DRIO traded down $0.09 during mid-day trading on Friday, hitting $9.00. 3,200 shares of the stock were exchanged, compared to its average volume of 8,597. The company has a market cap of $60.82 million, a P/E ratio of -0.81 and a beta of 1.08. The stock’s fifty day simple moving average is $11.09 and its two-hundred day simple moving average is $11.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55. DarioHealth has a twelve month low of $5.93 and a twelve month high of $17.74.

Institutional Investors Weigh In On DarioHealth

A number of hedge funds and other institutional investors have recently bought and sold shares of DRIO. Geode Capital Management LLC raised its position in DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after purchasing an additional 31,063 shares during the last quarter. XTX Topco Ltd boosted its stake in DarioHealth by 229.0% in the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after purchasing an additional 43,513 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of DarioHealth during the fourth quarter worth $35,000. 33.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on DRIO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Wall Street Zen lowered DarioHealth from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Finally, Stifel Nicolaus set a $16.00 price objective on DarioHealth in a report on Friday, November 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DarioHealth presently has an average rating of “Hold” and a consensus price target of $38.00.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.